NTRK基因融合-话题@MedSci

#NTRK基因融合#

11篇内容 | 1302人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2206003, encodeId=ac4222060039f, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=J Clin Pathol：NTRK基因改变在肝样胃癌中的特异性富集, objectType=article, longId=827035, objectId=172e82e0351e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240511/c85ba79c3a0e46d6bf82550d17f96349-tVydQy6Y4qth.jpg, objectUrl=/article/show_article.do?id=172e82e0351e, replyNumber=0, likeNumber=69, createdTime=2024-05-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=172e82e0351e, moduleTitle=J Clin Pathol：NTRK基因改变在肝样胃癌中的特异性富集, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=172e82e0351e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2174222, encodeId=636521e422226, content=<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a> <a href='/topic/show?id=bfc6e9573bd' target=_blank style='color:#2F92EE;'>#罕见癌症#</a> <a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a> <a href='/topic/show?id=1a1d104151ab' target=_blank style='color:#2F92EE;'>#神经营养酪氨酸受体激酶#</a>, objectTitle=病理干货 | NTRK基因融合在实体瘤中的广谱性、突变率和诊断策略, objectType=article, longId=804515, objectId=b37b8045159e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/patient-meeting-a-doctor-PAYSRMZ.jpg, objectUrl=/article/show_article.do?id=b37b8045159e, replyNumber=0, likeNumber=81, createdTime=2023-12-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b37b8045159e, moduleTitle=病理干货 | NTRK基因融合在实体瘤中的广谱性、突变率和诊断策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b37b8045159e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1618665, encodeId=eb751618665af, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准, objectType=article, longId=198676, objectId=870a1986e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870a1986e628, replyNumber=0, likeNumber=89, createdTime=2020-08-05, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870a1986e628, moduleTitle=Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=870a1986e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618664, encodeId=855b161866490, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤, objectType=article, longId=196520, objectId=4e2c19652009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2c19652009, replyNumber=0, likeNumber=149, createdTime=2020-06-27, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2c19652009, moduleTitle=又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2c19652009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618663, encodeId=607a161866354, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=NTRK基因融合性肿瘤的治疗：larotrectinib即将在日本上市, objectType=article, longId=194691, objectId=1a6f1946914b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a6f1946914b, replyNumber=0, likeNumber=74, createdTime=2020-05-26, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a6f1946914b, moduleTitle=NTRK基因融合性肿瘤的治疗：larotrectinib即将在日本上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a6f1946914b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618662, encodeId=ed51161866262, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤, objectType=article, longId=192797, objectId=6bd8192e9745, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bd8192e9745, replyNumber=0, likeNumber=95, createdTime=2020-04-24, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bd8192e9745, moduleTitle=英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bd8192e9745)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618661, encodeId=06d9161866155, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=拜耳TRK抑制剂Vitrakvi获得欧盟批准治疗NTRK基因融合的肿瘤患者, objectType=article, longId=180106, objectId=b99c180106aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b99c180106aa, replyNumber=0, likeNumber=98, createdTime=2019-09-28, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b99c180106aa, moduleTitle=拜耳TRK抑制剂Vitrakvi获得欧盟批准治疗NTRK基因融合的肿瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b99c180106aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618660, encodeId=4462161866032, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, objectType=article, longId=177801, objectId=78401e780141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78401e780141, replyNumber=0, likeNumber=0, createdTime=2019-08-18, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78401e780141, moduleTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78401e780141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618659, encodeId=eb5216186592a, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=加拿大卫生部批准VITRAKVI®（larotrectinib）治疗NTRK基因融合的晚期实体瘤, objectType=article, longId=176548, objectId=f7e11e654865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7e11e654865, replyNumber=0, likeNumber=90, createdTime=2019-08-01, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7e11e654865, moduleTitle=加拿大卫生部批准VITRAKVI®（larotrectinib）治疗NTRK基因融合的晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7e11e654865)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618658, encodeId=d54c161865804, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=EMA建议批准Vitrakvi治疗NTRK基因融合的实体瘤患者, objectType=article, longId=176376, objectId=d5511e6376a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5511e6376a5, replyNumber=0, likeNumber=83, createdTime=2019-07-30, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5511e6376a5, moduleTitle=EMA建议批准Vitrakvi治疗NTRK基因融合的实体瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5511e6376a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618657, encodeId=8eb8161865e53, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=泛癌种靶向药在日本获批用于治疗NTRK基因融合晚期复发实体瘤, objectType=article, longId=168843, objectId=cbc71688433a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbc71688433a, replyNumber=0, likeNumber=101, createdTime=2019-06-22, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbc71688433a, moduleTitle=泛癌种靶向药在日本获批用于治疗NTRK基因融合晚期复发实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbc71688433a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618656, encodeId=dc0d16186569d, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=拜耳公布larotrectinib治疗NTRK基因融合阳性转移性非小细胞肺癌患者的亚组分析结果, objectType=article, longId=164175, objectId=36571641e5d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36571641e5d2, replyNumber=0, likeNumber=103, createdTime=2019-04-14, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36571641e5d2, moduleTitle=拜耳公布larotrectinib治疗NTRK基因融合阳性转移性非小细胞肺癌患者的亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36571641e5d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618655, encodeId=ce0d1618655c8, content=<a href='/topic/show?id=b7f213129f5' target=_blank style='color:#2F92EE;'>#NTRK基因融合#</a>, objectTitle=罗氏的entrectinib获得FDA的快速审查用于治疗NTRK基因融合肿瘤, objectType=article, longId=160643, objectId=df3616064305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df3616064305, replyNumber=0, likeNumber=86, createdTime=2019-02-22, rootId=0, userName=12498dabm83暂无昵称, userId=366d19925131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df3616064305, moduleTitle=罗氏的entrectinib获得FDA的快速审查用于治疗NTRK基因融合肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df3616064305)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NTRK基因融合

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #NTRK基因融合#

J Clin Pathol：NTRK基因改变在肝样胃癌中的特异性富集

2024-05-22发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#实体瘤# #罕见癌症# #NTRK基因融合# #神经营养酪氨酸受体激酶#

病理干货 | NTRK基因融合在实体瘤中的广谱性、突变率和诊断策略

2023-12-11发表于上海

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准

2020-08-05

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤

2020-06-27

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

NTRK基因融合性肿瘤的治疗：larotrectinib即将在日本上市

2020-05-26

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤

2020-04-24

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

拜耳TRK抑制剂Vitrakvi获得欧盟批准治疗NTRK基因融合的肿瘤患者

2019-09-28

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC

2019-08-18

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

加拿大卫生部批准VITRAKVI®（larotrectinib）治疗NTRK基因融合的晚期实体瘤

2019-08-01

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

EMA建议批准Vitrakvi治疗NTRK基因融合的实体瘤患者

2019-07-30

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

泛癌种靶向药在日本获批用于治疗NTRK基因融合晚期复发实体瘤

2019-06-22

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

拜耳公布larotrectinib治疗NTRK基因融合阳性转移性非小细胞肺癌患者的亚组分析结果

2019-04-14

12498dabm83暂无昵称 (审核中...)

前往app查看评论内容

#NTRK基因融合#

罗氏的entrectinib获得FDA的快速审查用于治疗NTRK基因融合肿瘤

2019-02-22

科室
- - 订阅+
  - 更多科室
工具
服务